HomeCompareTRKYY vs JNJ

TRKYY vs JNJ: Dividend Comparison 2026

TRKYY yields 6.77% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRKYY wins by $36318.49M in total portfolio value
10 years
TRKYY
TRKYY
● Live price
6.77%
Share price
$1.80
Annual div
$0.12
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$36318.52M
Annual income
$35,315,909,402.35
Full TRKYY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TRKYY vs JNJ

📍 TRKYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRKYYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRKYY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRKYY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRKYY
Annual income on $10K today (after 15% tax)
$575.17/yr
After 10yr DRIP, annual income (after tax)
$30,018,522,992.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TRKYY beats the other by $30,018,519,006.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRKYY + JNJ for your $10,000?

TRKYY: 50%JNJ: 50%
100% JNJ50/50100% TRKYY
Portfolio after 10yr
$18159.28M
Annual income
$17,657,957,045.88/yr
Blended yield
97.24%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TRKYY
No analyst data
Altman Z
0.5
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRKYY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRKYYJNJ
Forward yield6.77%2.13%
Annual dividend / share$0.12$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$36318.52M$30.3K
Annual income after 10y$35,315,909,402.35$4,689.40
Total dividends collected$36249.52M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TRKYY vs JNJ ($10,000, DRIP)

YearTRKYY PortfolioTRKYY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$12,053$1,353.33$10,592$272.30+$1.5KTRKYY
2$15,946$3,049.01$11,289$357.73+$4.7KTRKYY
3$24,602$7,539.65$12,123$472.89+$12.5KTRKYY
4$48,067$21,742.67$13,141$629.86+$34.9KTRKYY
5$130,834$79,402.54$14,408$846.81+$116.4KTRKYY
6$543,969$403,976.72$16,021$1,151.60+$527.9KTRKYY
7$3,721,516$3,139,469.58$18,122$1,588.22+$3.70MTRKYY
8$44,128,574$40,146,551.76$20,930$2,228.20+$44.11MTRKYY
9$937,021,710$889,804,135.69$24,792$3,191.91+$937.00MTRKYY
10$36,318,522,632$35,315,909,402.35$30,274$4,689.40+$36318.49MTRKYY

TRKYY vs JNJ: Complete Analysis 2026

TRKYYStock

Türkiye Sinai Kalkinma Bankasi A.S. operates as a development and investment bank in Turkey and internationally. The company engages in the industrial investments, energy and resource efficiency, environmental investments, renewable energy, sustainable tourism, women's employment and equal opportunity, occupational health and safety, investments in developing regions, education and health investments, R&D and innovation, and working capital financing activities. It also provides project finance for energy generation and power plants; electricity distribution and natural gas distribution projects; mergers and acquisitions; logistics, transportation, and telecommunications; and public - private partnership projects. In addition, the company offers wholesale banking and SME financing, foreign trade finance, working capital financing, and machinery and equipment leasing services; letter of guarantees/external guarantees/letter of credits; and export/Eximbank endorsement, and country loans. Further, it provides corporate finance products and services, such as public offering preparation and brokerage, debt instrument issues, and mergers and acquisitions advisory; derivatives products, such as forwards, options, caps and floors, swaps, and swaptions; repo, warrant, and foreign derivative transactions; securities loans; brokerage for stock and bonds trading; and portfolio management and investment advisory services. Additionally, the company offers financial planning strategy, feasibility, valuation, and restructuring services, as well as sectoral analysis studies; and engineering and technical advisory, real estate appraisal, economic research, and sustainability consultancy services. Türkiye Sinai Kalkinma Bankasi A.S. was incorporated in 1950 and is headquartered in Istanbul, Turkey.

Full TRKYY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TRKYY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRKYY vs SCHDTRKYY vs JEPITRKYY vs OTRKYY vs KOTRKYY vs MAINTRKYY vs ABBVTRKYY vs MRKTRKYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.